Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Spironolactone/Hydrochlorothiazide Tablets (Viatris vs Neolpharma)
NCT06205407Phase 1Completed
- Sponsor
- Pfizer
- Start
- Dec 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of spironolactone and hydrochlorothiazide in hypertension (HTN) and edema (2 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity at 48 hours. Started Dec 2023; status: completed.
02
Drugs
spironolactonehydrochlorothiazide
03
Conditions
hypertension (HTN)edema
Beyond the preview
Go deeper on NCT06205407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205407.